A Phase I, Open-label, Single Dose, Single-Centre Study to Assess the Absolute Bioavailability of a Single Oral Dose of AZD9291 With Respect to an Intravenous Microdose of [14C]AZD9291 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 18 Oct 2016
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 08 Sep 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 31 Jul 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
- 14 Jul 2015 New trial record